Last update 01 Nov 2024

mTORC1 x Nav1.7 x mTORC2

Basic Info

Related Targets
mTORC1Nav1.7mTORC2

Related

1
Drugs associated with mTORC1 x Nav1.7 x mTORC2
XP-105
Target
Nav1.7 x mTORC1 x mTORC2
Mechanism
Nav1.7 blockers [+2]
Active Org.
Xynomic Pharmaceuticals, Inc.
Originator Org.
Boehringer Ingelheim GmbHBoehringer Ingelheim GmbH
Active Indication
Breast Cancer
Inactive Indication
Metastatic Solid Tumor [+1]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with mTORC1 x Nav1.7 x mTORC2
NCT01938846 / CompletedPhase 1
An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours
100 Clinical Results associated with mTORC1 x Nav1.7 x mTORC2
Login to view more data
100 Translational Medicine associated with mTORC1 x Nav1.7 x mTORC2
Login to view more data
0 Patents (Medical) associated with mTORC1 x Nav1.7 x mTORC2
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free